ALIM Alimera Sciences Inc

Price (delayed)

$4.335

Market cap

$30.02M

P/E Ratio

39.41

Dividend/share

N/A

EPS

$0.11

Enterprise value

$48.1M

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or ...

Highlights
The equity has soared by 178% year-on-year and by 149% since the previous quarter
Alimera Sciences's net income has surged by 136% YoY and by 130% QoQ

Key stats

What are the main financial stats of ALIM
Market
Shares outstanding
6.92M
Market cap
$30.02M
Enterprise value
$48.1M
Valuations
Price to earnings (P/E)
39.41
Price to book (P/B)
5.09
Price to sales (P/S)
0.54
EV/EBIT
5.81
EV/EBITDA
4.42
EV/Sales
0.81
Earnings
Revenue
$59.16M
EBIT
$8.27M
EBITDA
$10.88M
Free cash flow
$1.19M
Per share
EPS
$0.11
Free cash flow per share
$0.16
Book value per share
$0.85
Revenue per share
$8.05
TBVPS
$6.83
Balance sheet
Total assets
$62.1M
Total liabilities
$56.21M
Debt
$42.9M
Equity
$5.89M
Working capital
$34.93M
Liquidity
Debt to equity
7.28
Current ratio
4.39
Quick ratio
3.87
Net debt/EBITDA
1.66
Margins
EBITDA margin
18.4%
Gross margin
88.3%
Net margin
3.9%
Operating margin
8.7%
Efficiency
Return on assets
4.5%
Return on equity
N/A
Return on invested capital
14.2%
Return on capital employed
16%
Return on sales
14%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALIM stock price

How has the Alimera Sciences stock price performed over time
Intraday
-7.77%
1 week
-5.56%
1 month
-33.51%
1 year
-14.16%
YTD
2.73%
QTD
-52.36%

Financial performance

How have Alimera Sciences's revenue and profit performed over time
Revenue
$59.16M
Gross profit
$52.26M
Operating income
$5.15M
Net income
$2.32M
Gross margin
88.3%
Net margin
3.9%
Alimera Sciences's net income has surged by 136% YoY and by 130% QoQ
ALIM's net margin has surged by 133% year-on-year and by 124% since the previous quarter
Alimera Sciences's gross profit has increased by 28% from the previous quarter and by 10% YoY
The revenue rose by 25% since the previous quarter and by 8% year-on-year

Growth

What is Alimera Sciences's growth rate over time

Valuation

What is Alimera Sciences stock price valuation
P/E
39.41
P/B
5.09
P/S
0.54
EV/EBIT
5.81
EV/EBITDA
4.42
EV/Sales
0.81
The EPS has soared by 109% YoY and by 108% from the previous quarter
The equity has soared by 178% year-on-year and by 149% since the previous quarter
The stock's P/S is 64% less than its 5-year quarterly average of 1.5 and 33% less than its last 4 quarters average of 0.8
The revenue rose by 25% since the previous quarter and by 8% year-on-year

Efficiency

How efficient is Alimera Sciences business performance
Alimera Sciences's return on assets has surged by 134% YoY and by 128% QoQ

Dividends

What is ALIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALIM.

Financial health

How did Alimera Sciences financials performed over time
Alimera Sciences's total assets is 10% more than its total liabilities
Alimera Sciences's quick ratio has surged by 81% QoQ and by 42% YoY
The current ratio has surged by 62% since the previous quarter and by 37% year-on-year
The equity has soared by 178% year-on-year and by 149% since the previous quarter
ALIM's debt is down by 4.2% since the previous quarter and by 2.4% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.